Shenzhen Hornetcorn Bio-technology Company, LTD

Quick facts

Phase 2 pipeline

• Ag-D-CIK · Oncology
  Ag-D-CIK is a monoclonal antibody that targets CD47.
• DC-CTL · Oncology
  DC-CTL is a type of immunotherapy that uses genetically modified T cells to target and kill cancer cells.

Phase 1 pipeline

• D-CIK

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Shenzhen Hornetcorn Bio-technology Company, LTD portfolio CI brief
• Shenzhen Hornetcorn Bio-technology Company, LTD pipeline updates RSS